Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, Public Health England, 61 Colindale Avenue, London, UK.
J Antimicrob Chemother. 2013 Nov;68(11):2667-74. doi: 10.1093/jac/dkt212. Epub 2013 Jun 13.
The UK saw major increases in cephalosporin and quinolone resistance amongst Enterobacteriaceae from 2001 to 2006, with cephalosporin resistance largely reflecting dissemination of CTX-M extended-spectrum β-lactamases (ESBLs). We review subsequent trends.
Data were extracted from Public Health England's national database (LabBase), which collects susceptibility results for bloodstream isolates from hospital microbiology laboratories in England, Wales and Northern Ireland, and from the BSAC Bacteraemia Resistance Surveillance System, which centrally tests bloodstream isolates from 25-40 sentinel UK and Irish laboratories. Reference laboratory submissions were also reviewed.
LabBase and BSAC data showed that rates of non-susceptibility to cephalosporins and quinolones rose amongst Escherichia coli and Klebsiella spp. until mid-decade (2004-07) before plateauing or falling; similar falls in non-susceptibility began slightly earlier in Enterobacter spp. These reversals in trend occurred whilst the incidence of E. coli bacteraemias was rising, the incidence of Klebsiella bacteraemias was stable and the incidence of Enterobacter bacteraemias was falling; they were not paralleled in EARS-Net data for continental Europe and did not reflect the displacement of single mechanisms. They coincided with large reductions in hospital cephalosporin and quinolone use, owing to concern about Clostridium difficile, with replacement by penicillin/β-lactamase inhibitor combinations, which have borderline activity against ESBL producers, but consistently lack activity against carbapenemase producers.
Non-susceptibility to cephalosporins and quinolones has declined among bloodstream Enterobacteriaceae in the UK, probably reflecting prescribing shifts. The penicillin/β-lactamase inhibitor combinations that have largely replaced cephalosporins and quinolones may add to selection for carbapenemase producers.
2001 年至 2006 年期间,英国肠杆菌科的头孢菌素和喹诺酮耐药性大幅增加,其中头孢菌素耐药性主要反映了 CTX-M 型扩展谱β-内酰胺酶(ESBLs)的传播。我们回顾了随后的趋势。
从英国公共卫生部的国家数据库(LabBase)中提取数据,该数据库收集了英格兰、威尔士和北爱尔兰医院微生物实验室血流分离株的药敏结果,以及从 BSAC 菌血症耐药监测系统中提取的数据,该系统集中测试了来自 25-40 家英国和爱尔兰哨点实验室的血流分离株。还审查了参考实验室的提交结果。
LabBase 和 BSAC 数据显示,大肠埃希菌和克雷伯菌属对头孢菌素和喹诺酮的非敏感性率在年中(2004-07 年)之前上升,然后趋于平稳或下降;肠杆菌属的非敏感性下降开始得稍早。这些趋势的逆转发生在大肠埃希菌菌血症的发病率上升、克雷伯菌菌血症的发病率稳定和肠杆菌菌血症的发病率下降的同时;这与欧洲大陆的 EARS-Net 数据不一致,也没有反映单一机制的取代。它们与医院头孢菌素和喹诺酮使用量的大幅减少相吻合,这是由于对艰难梭菌的担忧,而青霉素/β-内酰胺酶抑制剂联合用药取代了头孢菌素和喹诺酮,这些药物对 ESBL 产生菌具有边缘活性,但对碳青霉烯酶产生菌始终缺乏活性。
英国血流肠杆菌科对头孢菌素和喹诺酮的耐药性下降,可能反映了处方的改变。青霉素/β-内酰胺酶抑制剂联合用药在很大程度上取代了头孢菌素和喹诺酮,可能会增加对碳青霉烯酶产生菌的选择。